220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

123non-compliance Failure to take prescription drugs properly; → seecompliance.non-conventional medicine syn. alternative or complementary ortraditional medicine; → see alternative medicine.non-evaluable patient At the end of clinical trials there are almostregularly good arguments to exclude data of some patients forparts of the efficacy analyses, e.g. for the following reasons: earlydrop-out, non-responder with progression of disease, violation ofinclusion or exclusion criteria, lack of compliance, intercurrentillness, comedication which was not allowed by the protocol,a.s.o.; → see also intent-to-treat analysis.non-experimental trial → see non-interventional trial.non-interventional trial syn. non-experimental trial; EU: “a clinicaltrial where the selection of subjects or the attribution of medicinalproducts or the examinations carried out or medical and biologicalfollow-up of subjects falls within current medical practice”;→ see also post marketing surveillance.non-new molecular entities (non-NME), → see mee-too.non-prescription drug → see over-the-counter.non-renewal → see withdrawal.non-therapeutic study Study without any therapeutic benefit for thesubject; → see also phase i.Nordic Council on Medicines (NLN) Forum of cooperation on drugaffaires between Denmark, Finland, Iceland, Norway, and Swedenwhich was set up in 1975 and produced the Nordic Guidelineson good clinical practice; → see also good clinical trialpractice.Nordic Guidelines Guidelines on good clinical practice produced bythe NLN and published first in 1989 one year before the EC guidelines;→ see good clinical trial practice.normal distribution → see distribution.normal range → see laboratory normal range.North American Free Trade Agreement (NAFTA) Agreement betweenthe US, Canada and Mexico for a free trade area with approx.360 million people and an annual economy of around 6,000,000million US $.note for guidance syn. guide, guideline; → see ec law.notice-of-change form → see data resolution form.notice-of-claimed investigational exemption for a new drug → seeinvestigational new drug.no-treatment-control Design comparing active treatment vs. notreatment;can be subject to severe bias due to the placebo- orhawthorne effect.nuisance variable → see confounder.nui